Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Applications of Mass Spectrometry

Daniel Chelsky's Biography



Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics Inc

Dr. Chelsky is the Chief Scientific Officer at Caprion Proteomics, a company using mass spectrometry to discover and validate biomarkers of disease and drug efficacy, drug mechanism of action and new targets for disease intervention. Previously he served as President of BioSignal, Inc., a subsidiary of PerkinElmer focused on G-protein coupled receptor related research and reagents. He has also held positions as Sr. Director of Biology at Pharmacopeia, a combinatorial chemistry company, Director of Drug Discovery at Onyx Pharmaceuticals, and Principal Investigator at DuPont Merck Pharmaceuticals. He received his Ph.D. at the University of Oregon and was an American Cancer Society fellow at the University of California, Berkeley.

Daniel Chelsky Image

Creating a Clinical Diagnostic Test from Discovery through Launch with Mass Spectrometry

Wednesday, 29 October 2014 at 09:15

Add to Calendar ▼2014-10-29 09:15:002014-10-29 10:15:00Europe/LondonCreating a Clinical Diagnostic Test from Discovery through Launch with Mass SpectrometryClinical Applications of Mass Spectrometry in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com

Hundreds of candidate protein biomarkers can be rapidly triaged, using MRM mass spectrometry, without the use of antibodies.  A case study will be presented that led to a commercialized test for benign vs. malignant pulmonary nodules.


Add to Calendar ▼2014-10-29 00:00:002014-10-30 00:00:00Europe/LondonClinical Applications of Mass SpectrometryClinical Applications of Mass Spectrometry in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com